EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

Laura J Else, Laura Dickinson, Stacey Edick, Ashley Zyhowski, Ken Ho, Leslie Meyn, Sujan Dilly-Penchala, Beth Thompson, Victoria Shaw, Saye Khoo, Rhonda M Brand

Journal of Antimicrobial Chemotherapy · 01.07.2024 · 79 (7) · 1597-1605

DOI: 10.1093/jac/dkae147 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.05.2024. Verfasst von Laura J Else und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Pyridones, Oxazines, Heterocyclic Compounds, 3-Ring, Emtricitabine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor adherence to ART and pre-exposure prophylaxis (PrEP) can impact patient and public health. Point-of-care testing (POCT) may aid monitoring and adherence interventions.

Objectives

We report the pharmacokinetics of tenofovir [dosed as tenofovir disoproxil (TDF) and tenofovir alafenamide (TAF)], emtricitabine (FTC), lamivudine (3TC) and dolutegravir (DTG) in plasma and urine following drug cessation to evaluate adherence targets in urine for POCT.

Methods

Subjects were randomized (1:1) to receive DTG/FTC/TAF or DTG/3TC/TDF for 15 days. Plasma and spot urine were collected on Day 15 (0–336 h post final dose). Drug concentrations were quantified using LC-MS, and non-linear mixed-effects models applied to determine drug disposition between matrices and relationship with relevant plasma [dolutegravir protein-adjusted 90% inhibitory concentration (PA-IC90 = 64 ng/mL) and minimum effective concentration (MEC = 324 ng/mL)] and urinary thresholds [tenofovir disoproxil fumarate 1500 ng/mL].

Results

Of 30 individuals enrolled, 29 were included (72% female at birth, 90% Caucasian). Median (range) predicted time to plasma dolutegravir PA-IC90 and MEC were 83.5 (41.0–152) and 49.0 h (23.7–78.9), corresponding to geometric mean (90%) urine concentrations of 5.42 (4.37–6.46) and 27.4 ng/mL (22.1–32.7). Tenofovir in urine reached 1500 ng/mL by 101 h (58.6–205) with an equivalent plasma concentration of 6.20 ng/mL (4.21–8.18).

Conclusions

These data support use of a urinary tenofovir threshold of <1500 ng/mL (tenofovir disoproxil fumarate-based regimens) as a marker of three or more missed doses for a POCT platform. However, due to low dolutegravir concentrations in urine, POCT would be limited to a readout of recent dolutegravir intake (one missed dose).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesOxazinesHeterocyclic Compounds, 3-RingEmtricitabinePiperazinesLamivudinePoint-of-Care TestingHIV InfectionsTenofovirAnti-HIV AgentsHumansMaleAdultFemaleMiddle AgedPre-Exposure ProphylaxisYoung AdultPlasmaMedication AdherenceDolutegravir

Substanzen

PyridonesOxazinesHeterocyclic Compounds, 3-RingEmtricitabinePiperazinesLamivudineTenofovirAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Magee-Womens Research Institute, Pittsburgh, PA, USA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., Meyn, L., Dilly-Penchala, S., Thompson, B., Shaw, V., Khoo, S., & Brand, R. M. (2024). Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing. Journal of Antimicrobial Chemotherapy, 79(7), 1597-1605. https://doi.org/10.1093/jac/dkae147

Vancouver

Else LJ, Dickinson L, Edick S, Zyhowski A, Ho K, Meyn L, et al. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing. Journal of Antimicrobial Chemotherapy. 2024;79(7):1597-1605. doi:10.1093/jac/dkae147

BibTeX
@article{Else2024,
  author = {Else, Laura J and Dickinson, Laura and Edick, Stacey and Zyhowski, Ashley and Ho, Ken and Meyn, Leslie and Dilly-Penchala, Sujan and Thompson, Beth and Shaw, Victoria and Khoo, Saye and Brand, Rhonda M},
  title = {Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {7},
  pages = {1597--1605},
  doi = {10.1093/jac/dkae147}
}
Kostenlos starten →